Bayer shares move as US commercial rollout of SUNHARBO begins
FROM THE WIRE · FINANCE.YAHOO.COM
Bayer (XTRA:BAYN) has just started U.S. commercial rollout of SUNHARBO, a first in class oral Factor XIa inhibitor for secondary stroke prevention. This gives investors a fresh data point on its pharmaceuticals pipeline. The SUNHARBO launch lands at a time when Bayer's share…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe US launch of a drug is relevant for Bayer shares, which remain exposed to Roundup and earnings risks.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bayer has started the US commercial rollout of SUNHARBO for secondary stroke prevention.
- 02Shares are up 40.42% year to date and delivered a 93.99% total shareholder return over one year.
- 03The stock fell 5.59% in the last seven days and trades below the average analyst price target.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets